Gilead Sciences (GILD) Revenue (2009 - 2026)

Gilead Sciences (GILD) has reported Revenue for 18 consecutive years, with $7.0 billion the latest figure, recorded in Q1 2026.

• Revenue for Q1 2026 came in at $7.0 billion, up 4.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.7 billion (up 3.48% YoY), and the FY2025 annual result was $29.4 billion, up 2.4% from the prior year.
• Revenue was $7.0 billion for Q1 2026 at Gilead Sciences, down from $7.9 billion in the prior quarter.
• Over five years, Revenue peaked at $7.9 billion in Q4 2025 and troughed at $6.3 billion in Q2 2022.
• Average Revenue over 5 years is $7.0 billion, with a median of $7.0 billion recorded in 2022.
• Year-over-year, Revenue dropped 5.11% in 2022 and grew 7.01% in 2024.
• Over 5 years, Revenue stood at $7.4 billion in 2022, then slipped by 3.72% to $7.1 billion in 2023, then gained by 6.4% to $7.6 billion in 2024, then rose by 4.7% to $7.9 billion in 2025, then fell by 12.18% to $7.0 billion in 2026.
• Per Business Quant data, the three most recent Revenue figures were $7.0 billion in Q1 2026, $7.9 billion in Q4 2025, and $7.8 billion in Q3 2025.